Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk that became the first GLP-1 drug approved specifically for weight management. Marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for chronic weight management (approved 2014), liraglutide paved the way for the current generation of GLP-1 weight loss medications, including its successor semaglutide. While semaglutide has since surpassed it in both efficacy and dosing convenience, liraglutide remains an important treatment option with the longest real-world safety track record of any GLP-1 agonist and one of only a few such drugs approved for adolescents.
Liraglutide is administered as a once-daily subcutaneous injection. For weight management, the dose is titrated over five weeks from 0.6 mg to a maintenance dose of 3.0 mg daily. Clinical trials demonstrated average weight loss of 6 to 8% of body weight over 56 weeks, with meaningful improvements in cardiometabolic risk factors.
What Is Liraglutide?
Liraglutide is an acylated analog of human GLP-1, the incretin hormone released by intestinal L-cells after eating. It was developed by Novo Nordisk through deliberate modification of the native GLP-1(7-37) peptide to create a molecule suitable for once-daily dosing. Liraglutide shares 97% amino acid sequence homology with endogenous human GLP-1, with one key substitution (Lys34Arg) and the attachment of a C-16 palmitic acid chain via a glutamic acid spacer at position 26.
These structural modifications give liraglutide three properties that extend its duration of action far beyond the 2-minute half-life of native GLP-1. The fatty acid chain promotes self-association into heptamers at the injection site, slowing absorption. Once in the bloodstream, the palmitate chain binds reversibly to serum albumin (approximately 99% protein binding), creating a circulating reservoir from which free liraglutide is released gradually. Albumin binding also provides partial protection from degradation by dipeptidyl peptidase-4 (DPP-4). The result is a plasma half-life of approximately 13 hours, supporting once-daily dosing.
Liraglutide was first approved by the European Medicines Agency (EMA) in 2009 and by the FDA in January 2010 as Victoza for type 2 diabetes. Following the SCALE clinical trial program, it received a second FDA approval in December 2014 as Saxenda for chronic weight management, making it the first GLP-1 agonist approved for obesity treatment. Since then, generic versions from Teva, Hikma, and other manufacturers have become available following patent expiration in 2024.
Although semaglutide (Ozempic/Wegovy) has largely overtaken liraglutide in clinical preference due to its weekly dosing and greater weight loss efficacy, liraglutide retains several advantages: it has over 15 years of post-marketing safety data, cardiovascular outcome data from the landmark LEADER trial, and pediatric approvals for both diabetes and obesity. For a full head-to-head breakdown, see liraglutide vs semaglutide.
The primary benefits of liraglutide include:
- Clinically meaningful weight loss (6 to 8% average, up to 10%+ in early responders)
- Improved glycemic control and HbA1c reduction in type 2 diabetes
- Demonstrated cardiovascular risk reduction (13% reduction in MACE in the LEADER trial)
- Reduced progression from prediabetes to type 2 diabetes
- Approved for adolescents aged 12+ (obesity) and children aged 10+ (diabetes)
- The longest safety track record of any GLP-1 receptor agonist
How It Works
GLP-1 Receptor Activation
Liraglutide functions as a potent agonist at GLP-1 receptors distributed throughout the pancreas, brain, heart, and gastrointestinal tract. When it binds to receptors on pancreatic beta cells, it stimulates glucose-dependent insulin secretion, meaning insulin is released only when blood glucose is elevated. At the same time, liraglutide suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. This dual pancreatic action improves postprandial and fasting glucose levels without the hypoglycemia risk associated with sulfonylureas or exogenous insulin when used as monotherapy.
Appetite Suppression and Satiety
The weight loss effects of liraglutide are primarily centrally mediated. GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem nucleus tractus solitarius regulate hunger and satiety signals. Liraglutide activates these receptors to reduce appetite, enhance meal-related satiety, and diminish food-reward pathways that drive hedonic eating. Functional neuroimaging studies have shown that liraglutide decreases activation in brain regions associated with food craving when subjects are exposed to food cues.
Gastric Emptying
Liraglutide slows the rate at which food leaves the stomach, contributing to prolonged feelings of fullness and reduced caloric intake per meal. This delayed gastric emptying also blunts post-meal glucose excursions by slowing carbohydrate absorption. However, unlike semaglutide, some evidence suggests that the gastric emptying effects of liraglutide may attenuate with chronic use through tachyphylaxis, while the appetite-suppressing central effects remain sustained.
Cardiovascular Effects
Beyond glucose and weight management, liraglutide exerts direct and indirect cardiovascular benefits. The LEADER trial demonstrated reduced rates of major adverse cardiovascular events (MACE). Proposed mechanisms include reduced inflammation, improved endothelial function, decreased blood pressure, improved lipid profiles, and direct cardioprotective effects via GLP-1 receptors expressed on cardiomyocytes. Weight loss itself also contributes to cardiovascular risk reduction.
Pharmacokinetic Differences From Semaglutide
Both liraglutide and semaglutide work through the same GLP-1 receptor, but their pharmacokinetic profiles differ substantially. Semaglutide has a half-life of approximately 7 days (vs 13 hours for liraglutide), achieved through a larger C-18 fatty diacid chain and an amino acid substitution at position 8 that confers greater DPP-4 resistance. These differences translate to weekly dosing for semaglutide versus daily for liraglutide, and approximately double the weight loss efficacy in head-to-head trials.
Dosage Protocols
Liraglutide dosing differs by indication. Both protocols use gradual titration to minimize gastrointestinal side effects. At any stage, dose escalation can be delayed by one additional week if side effects are not tolerable.
Weight Management (Saxenda Protocol):
- Week 1: 0.6 mg once daily
- Week 2: 1.2 mg once daily
- Week 3: 1.8 mg once daily
- Week 4: 2.4 mg once daily
- Week 5 onward: 3.0 mg once daily (maintenance)
Type 2 Diabetes (Victoza Protocol):
- Week 1: 0.6 mg once daily (titration only, not effective for glycemic control)
- Week 2 onward: 1.2 mg once daily
- If additional control is needed: 1.8 mg once daily (maximum)
How to Use / Administration Methods
Liraglutide is supplied in pre-filled, multi-dose injection pens that require no reconstitution or mixing. Both Saxenda and Victoza pens use fine-gauge needles and are designed for self-administration.
Injection Procedure:
- Allow the pen to reach room temperature if refrigerated (15 to 30 minutes)
- Attach a new pen needle for each injection
- Prime the pen by dialing to the flow check symbol and pressing the dose button until a drop appears at the needle tip
- Dial to the prescribed dose
- Clean the injection site with an alcohol swab
- Pinch the skin at the abdomen, thigh, or upper arm
- Insert the needle at a 90-degree angle and press the dose button fully
- Hold the button for 6 seconds before withdrawing
- Do not rub the injection site
Liraglutide can be injected at any time of day, independent of meals, though many users find that evening dosing reduces nausea interference with daytime eating. The injection site should be rotated to prevent lipodystrophy. If a dose is missed, skip it and resume the normal schedule the next day. Do not take a double dose.
Results Timelines
Weeks 1 to 2 (0.6 to 1.2 mg): Initial appetite suppression is often noticeable within the first few days. Modest weight loss of 1 to 2 kg may occur, partly from reduced caloric intake and partly from fluid shifts. Nausea is most common during this period. Blood glucose improvements begin in patients with diabetes.
Weeks 3 to 8 (1.8 to 3.0 mg): As the dose reaches maintenance levels, appetite reduction becomes more consistent. Weight loss typically accelerates to 0.5 to 1.0 kg per week. Gastrointestinal side effects peak during dose escalation but begin to stabilize. Most patients achieve 3 to 5% weight loss by week 8.
Weeks 8 to 16 (3.0 mg): This period is clinically important for assessing response. Prescribing guidelines recommend evaluating whether 4% body weight has been lost by week 16. Early responders (those who lose 4%+ by this point) go on to achieve significantly greater total weight loss (average 10.8%) compared to non-responders (average 3.0%).
Weeks 16 to 56 (3.0 mg): Continued use produces progressive weight loss that typically plateaus between weeks 40 and 56. The SCALE Obesity and Prediabetes trial reported mean weight loss of 8.0% versus 2.6% with placebo at 56 weeks, with 33.1% of liraglutide-treated patients achieving 10% or greater weight loss.
Research Evidence
The clinical evidence for liraglutide spans two major trial programs: SCALE for weight management and LEADER for cardiovascular outcomes.
SCALE Obesity and Prediabetes: The pivotal trial enrolled 3,731 adults with BMI of 30 or greater (or 27 or greater with comorbidities) without diabetes. Published in the New England Journal of Medicine in 2015 by Pi-Sunyer et al., it randomized participants 2:1 to liraglutide 3.0 mg or placebo, both with lifestyle counseling. Liraglutide produced a mean placebo-adjusted weight loss of 5.4 kg (approximately 5.4% additional weight reduction beyond placebo). More than 63% of liraglutide-treated patients lost at least 5% of body weight versus 27% with placebo. A 3-year extension showed that liraglutide reduced progression from prediabetes to type 2 diabetes by 79%.
SCALE Diabetes: In 846 patients with type 2 diabetes, liraglutide 3.0 mg achieved 6.0% weight loss versus 2.0% with placebo over 56 weeks, with 54.3% of patients achieving 5% or greater weight loss. HbA1c was also significantly reduced.
SCALE Maintenance: This trial demonstrated that liraglutide could sustain and extend weight loss initially achieved through caloric restriction. Participants who had already lost at least 5% of body weight on a low-calorie diet were randomized to liraglutide or placebo. Those on liraglutide lost an additional 6.2% versus 0.2% with placebo over 56 weeks.
SCALE IBT: When combined with intensive behavioral therapy, liraglutide 3.0 mg produced 7.5% mean weight loss versus 4.0% with behavioral therapy plus placebo.
LEADER Cardiovascular Outcomes Trial: The landmark cardiovascular outcome trial randomized 9,340 patients with type 2 diabetes and high cardiovascular risk to liraglutide (1.8 mg) or placebo over a median follow-up of 3.8 years. Published in the New England Journal of Medicine in 2016, LEADER demonstrated a 13% reduction in the primary composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (HR 0.87; 95% CI, 0.78 to 0.97; P=0.01). Cardiovascular death was reduced by 22% (HR 0.78) and all-cause mortality by 15% (HR 0.85). LEADER also showed a significant reduction in renal outcomes, driven primarily by reduced new-onset macroalbuminuria. These results established liraglutide as one of the first diabetes medications to demonstrate a cardiovascular mortality benefit. Importantly, these cardiovascular benefits were demonstrated specifically in the LEADER population: patients with type 2 diabetes at high cardiovascular risk. They should not be generalized to all liraglutide users, such as non-diabetic patients using Saxenda for weight management, for whom cardiovascular outcome data of this nature have not been established.
STEP 8 Head-to-Head Comparison: The STEP 8 trial directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in adults without diabetes. At 68 weeks, semaglutide produced 15.8% weight loss versus 6.4% with liraglutide. A significantly greater proportion of semaglutide patients achieved 10% or greater (70.9% vs 25.6%) and 15% or greater (55.0% vs 12.0%) weight loss. While this trial demonstrated semaglutide's superiority, it also confirmed that liraglutide produces clinically meaningful weight loss that exceeds lifestyle changes alone.
Pediatric Trial: A randomized controlled trial published in the New England Journal of Medicine in 2020 by Kelly et al. demonstrated that liraglutide 3.0 mg significantly reduced BMI standard deviation score in adolescents aged 12 to 17 with obesity, leading to the expanded pediatric approval.
Stacking
Liraglutide is sometimes used alongside other medications, though combinations should be approached with caution and medical supervision.
With metformin: This is the most well-established combination, commonly used in type 2 diabetes management. Metformin and liraglutide have complementary mechanisms, and their combined use is supported by extensive clinical data. Additive weight loss benefits have been observed.
With insulin: Victoza is approved for use alongside basal insulin in patients with type 2 diabetes. The SCALE Insulin trial demonstrated that adding liraglutide to basal insulin improved both weight and glycemic control. Hypoglycemia risk increases when liraglutide is combined with insulin, and insulin dose reduction may be necessary.
With other GLP-1 agonists: Simultaneous use of liraglutide with semaglutide, tirzepatide, or other GLP-1 agonists is not recommended. The mechanisms overlap completely, and combining them would dramatically increase gastrointestinal side effects without meaningful additional benefit.
With growth hormone peptides: Some users in the bodybuilding and fitness community combine liraglutide with growth hormone secretagogues such as ipamorelin or sermorelin for body recomposition. This combination is experimental and off-label. Caution is warranted as both compound classes affect glucose metabolism.
Reconstitution, Storage & Prep
Liraglutide requires no reconstitution. Both Victoza and Saxenda are supplied as clear, colorless solutions in pre-filled, multi-dose injection pens ready for immediate use.
Storage:
- Unused pens: Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Do not freeze. Protect from light.
- In-use pens: Store at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days. Discard after 30 days, even if medication remains.
- The pen cap should be replaced after each use to protect from light.
- Do not use if the solution appears cloudy, discolored, or contains particles.
Pen Supplies:
- Saxenda pen: 18 mg/3 mL (6 mg/mL), delivering doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg
- Victoza pen: 18 mg/3 mL (6 mg/mL), delivering doses of 0.6, 1.2, or 1.8 mg
- Pen needles: NovoFine or NovoTwist disposable needles (not included with pens)
Side Effects
Gastrointestinal adverse effects are the most common, particularly during dose escalation. They tend to be transient and usually improve within several weeks at a stable dose.
Frequent (greater than 20% incidence):
- Nausea (39%)
- Diarrhea (21%)
Very Common (10 to 20% incidence):
- Constipation (19%)
- Vomiting (16%)
- Headache
- Decreased appetite
- Dyspepsia
Common (1 to 10% incidence):
- Abdominal pain
- Fatigue
- Dizziness
- Injection site reactions
- Gastroesophageal reflux
- Flatulence
Rare but Serious:
- Pancreatitis (0.3% in clinical trials; discontinue immediately if suspected)
- Gallbladder disease and cholelithiasis (increased incidence with rapid weight loss)
- Acute kidney injury (usually secondary to severe dehydration from GI effects)
- Hypoglycemia (primarily when combined with insulin or sulfonylureas)
- Thyroid C-cell tumors (observed in rodent studies at clinically relevant exposures; human relevance uncertain)
- Allergic reactions and anaphylaxis (rare)
Liraglutide carries a boxed warning regarding thyroid C-cell tumor risk based on animal data. In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Mitigation strategies include strict adherence to the titration schedule, eating smaller and more frequent meals, avoiding high-fat and greasy foods, staying well hydrated, and eating slowly. Delaying dose escalation by one week is recommended if side effects are intolerable at a given dose level.
Legal Status / FDA
Liraglutide is FDA-approved and legally available by prescription in the United States under two brand names:
- Victoza (approved January 2010): Type 2 diabetes in adults and children aged 10+, dosed at 1.2 to 1.8 mg daily
- Saxenda (approved December 2014): Chronic weight management in adults with BMI of 30 or greater (or 27+ with a weight-related comorbidity) and adolescents aged 12+ with obesity, dosed at 3.0 mg daily
Liraglutide is not a controlled substance. It is classified as a prescription medication in all major markets.
Generic versions became available beginning in 2024 following patent expiration. Teva Pharmaceuticals launched the first authorized generic in the United States in June 2024, with Hikma receiving FDA approval for both generic Victoza and generic Saxenda in December 2024. Generic versions are also approved in the EU, UK, and Australia.
Internationally, liraglutide is approved by the European Medicines Agency (EMA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, Australia's TGA, and regulatory bodies in numerous other countries. Prescription requirements apply in all jurisdictions.
Unlike semaglutide, there is no oral formulation of liraglutide available. All approved forms require subcutaneous injection.
Sports/WADA Status
Liraglutide is not currently listed on the World Anti-Doping Agency (WADA) Prohibited List and is not banned in competitive sports as of the 2026 list. However, WADA is actively monitoring GLP-1 receptor agonists. Since 2024, WADA has funded the development of blood-based detection methods for liraglutide, semaglutide, and tirzepatide, as very little intact drug appears in urine. Beginning in 2026, markers of semaglutide and tirzepatide are being monitored under the WADA Monitoring Program to track potential misuse in and out of competition.
The monitoring program is a formal step that WADA uses to evaluate whether substances should move to the Prohibited List. While liraglutide itself is not yet subject to formal monitoring, WADA's stated interest in the GLP-1 class as a whole means that future prohibition is possible if evidence of performance-enhancing misuse or sport-spirit violations emerges.
Athletes subject to anti-doping testing should verify current regulations with their specific governing body, as policies vary across sports organizations. While GLP-1 agonists are not prohibited, their use in weight-class sports raises ethical questions about artificially manipulating body weight for competitive advantage.
Conclusion
Liraglutide holds an important place in the history of obesity pharmacotherapy as the first GLP-1 receptor agonist to receive regulatory approval for weight management. While its successor semaglutide offers greater weight loss efficacy and the convenience of weekly dosing, liraglutide remains a clinically validated option backed by extensive trial data and the longest real-world safety record in its class.
The SCALE trials established that daily liraglutide produces meaningful and sustained weight loss with improvements across cardiometabolic risk factors. The LEADER trial provided landmark evidence that liraglutide reduces cardiovascular death and major adverse cardiovascular events in patients with type 2 diabetes. And with pediatric approvals for both diabetes and obesity, liraglutide addresses clinical populations where treatment options remain limited.
For patients who prefer or require a daily dosing regimen, cannot tolerate semaglutide, or seek a GLP-1 agonist with the deepest safety evidence base, liraglutide continues to serve a meaningful role in modern metabolic medicine. The availability of generic versions beginning in 2024 has also made liraglutide a more accessible option for patients facing cost barriers to GLP-1 therapy. Those evaluating the broader GLP-1 landscape may also want to consider retatrutide, the investigational triple-agonist with preliminary data showing greater weight loss than any approved therapy.